RegulatoryCompany release

FDA approves Novartis' Cosentyx 150 mg for polymyalgia rheumatica

Novartis Pharma AG · Tue 17 Nov 2026

Novartis says Cosentyx is the first and only anti-IL-17 biologic cleared in the US for polymyalgia rheumatica, giving adults an option beyond long-term corticosteroids.

The US Food and Drug Administration has approved Novartis' Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica (PMR), the company announced on 17 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release: Novartis Pharma AG ↗

Article written by VigiEye from the official source (Novartis Pharma AG). Claims are the company's own. AI-assisted; check the source before acting.